In response to some recent successes by several companies operating in the cervical cancer space, we are issuing a two-part special report exploring pre-cervical cancer and CIN.
MTM Laboratories has developed a proprietary technological platform that has identified a novel biomarker that serves for the early detection of cervical cancer.
A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.
Ovatech of Auburndale, Mass., is developing the world’s first non-hormonal, female-controlled contraception device.
The idea of using harmful bacteria to treat disease might strike many as an odd concept.
Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.
A clinical trial by Guided Therapeutics (GT), a biotechnology company specializing in women’s health, found that current screening methods for cervical disease missed the disease nearly a third of the time.